# Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

> **NCT01656252** · PHASE1,PHASE2 · TERMINATED · sponsor: **PrECOG, LLC.** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Phase I- Cytarabine & Eltrombopag
- **DRUG:** Phase II- Sequence A
- **DRUG:** Phase II- Sequence B

## Key facts

- **NCT ID:** NCT01656252
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study stopped per Novartis request due to futility from another study.
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01656252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01656252, "Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01656252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*